Researchers are investigating whether low-dose lithium, a medication typically used to treat bipolar disorder, can mitigate the effects of Alzheimer's disease. While animal models show a reduction in brain damage, human clinical evidence is not yet conclusive.
How low-dose lithium reduced brain damage in engineered mice
Recent findings detailed in a perspective article in Translational Psychiatry suggest that low-dose lithium may serve as a protective agent for the brain. According to the report, researchers utilized mice genetically engineered to develop Alzheimer's, discovering that the administration of low-dose lithium improved memory performance and decreased visible signs of brain damage.
The mechanism behind this improvement appears to be the preservation of neural connections. The researchers believe that lithium helps protect the specific brain cells responsible for thinking and memory, effectively maintaining the communication pathways between different regions of the brain that are typically destroyed by the progression of dementia.
The link between lithium deficiency and 982,000 UK dementia cases
The interest in lithium is not new, but recent data provides a stronger biological rationale. A study published in the journal Nature found that individuals suffering from Alzheimer's disease exhibited lower levels of lithium in their brains compared to healthy individuals. This suggests a correlation between lithium deficiency and the acceleration of cognitive decline.
This discovery is particularly significant given the scale of the crisis in the United Kingdom, where dementia affects approximately 982,000 people. As the report notes, there is currently no known cure or preventative treatment for the condition. Because lithium is already a common, inexpensive medication prescribed by the NHS for bipolar disorder and depression, it represents a low-cost pharmacological avenue for a massive patient population.
Why Dr. Richard Oakley warns against premature conclusions
Despite the promising animal data, the transition to human treatment is fraught with uncertainty. Dr. Richard Oakley, the associate director of research and innovation at the Alzheimer's Society, cautioned that the current research does not yet prove that lithium can actually treat or prevent dementia in humans.. He noted that the discussion regarding lithium's role is growing, but the evidence remains preliminary.
A critical gap exists in the clinical data, as the human trials conducted on people with early-stage Alzheimer's have been small in scale. According to the source, there is currently no clear evidence that lithium has a meaningful impact on human patients. Until larger, more rigorous clinical trials are commpleted, the Alzheimer's Society maintains that lithium remains a promising avenue rather than a proven solution.
The role of plaque build-up in lithium deficiency
Beyond memory loss, lithium deficiency has been linked to the physical hallmarks of Alzheimer's. In animal models, a lack of lithium was shown to accelerate the build-up of plaque in the brain, a concrete biological marker associated with the disease's progression.
By reducing this plaque accumulation, low-dose lithium could potentially slow the physical dgeradation of the brain. However, the scientific community is still determining if the dosage required to clear plaque in mice can be safely replicated in humans without causing the toxicity often associated with higher doses of lithium used in psychiatric care.
Comments 0